A Diagnostic Model Built for Speed and Lower Cost of Care
A National, Clinically Driven Partner Redefining the Standard of Care
HealthTrack’s next-morning PCR results give clinicians the speed and clarity needed to act decisively. Timely, evidence-based treatments reduce unnecessary utilization, lower pharmacy pressure, and measurably improve patient outcomes. Our precision diagnostics cut avoidable costs and strengthen shared decision-making.
Contact Us
Let’s work together to use the power of fast, accurate diagnostic to revolutionize healthcare. Fill out the form below, and a member of our team will be in touch. Or call us at 866-287-3218.
A Diagnostic Model Built for Speed and Lower Cost of Care
A National, Clinically Driven Partner Redefining the Standard of Care
HealthTrack’s next-morning PCR results give clinicians the speed and clarity needed to act decisively. Timely, evidence-based treatments reduce unnecessary utilization, lower pharmacy pressure, and measurably improve patient outcomes. Our precision diagnostics cut avoidable costs and strengthen shared decision-making.
Contact Us
HealthTrack helps payors and providers achieve the promise of quality, affordable care —better outcomes, lower costs, and more efficient use of healthcare resources.
HealthTrack helps payors and providers achieve the promise of quality, affordable care —better outcomes, lower costs, and more efficient use of healthcare resources.
1 Hersh AL, King LM, Shapiro DJ, Hicks LA, Fleming-Dutra KE. Unnecessary Antibiotic Prescribing in US Ambulatory Care Settings, 2010-2015. Clinical Infectious Diseases. 2021;72(1):133-137.
2 Shehab N, Lovegrove MC, Geller AI, et al. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115-2125.
3 Centers for Disease Control and Prevention. (2025). Antimicrobial resistance: Causes and how it spreads.
4 Nelson, R. E., Hatfield, K. M., Wolford, H., et al. (2021). National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clinical Infectious Diseases, 72(Suppl 1), S17-S26.
5 Nature. 40 million deaths by 2050: Toll of drug-resistant infections to rise by 70%.
The Problem:
Slow Testing Drives Unnecessary Utilization
Traditional diagnostics leave providers without clear answers, forcing “just-in-case” antibiotic prescribing. This approach discourages testing, drives overprescription of broad-spectrum antibiotics, and contributes directly to increased follow-up visits, ED utilization, and higher overall system spending.
Escalating Costs & Impacts
- Up to 28% of outpatient antibiotics are prescribed unnecessarily.1
- 1 in 5 medication-related ED visits stems from antibiotic side effects.3
- $4.6 billion annually: The estimated cost to treat Americans with infections caused by antimicrobial resistant germs.4
Growing Resistance
- There are 2.8 million resistant infections in the U.S. annually.2
- Over 35,000 Americans die yearly from antimicrobial-resistant infections.2
- By 2050: The toll of drug-resistant infections is predicted to rise by 70%, leading to significant loss of life:5
- 40 million deaths globally each year5
- 2 million deaths in the U.S. each year5
The Problem:
Slow Testing Drives Unnecessary Utilization
Traditional methods take days to deliver results, leaving providers without clear answers and prescribing “just-in-case” antibiotics. This discourages testing, drives overprescription of broad-spectrum antibiotics, and fuels antimicrobial resistance—all which lead to higher costs and poorer outcomes.
Slow diagnostics also contribute directly to increased follow-up visits, ED utilization, and higher overall system spending.
Escalating Costs & Impacts
- Up to 28% of outpatient antibiotics are prescribed unnecessarily.1
- 1 in 5 medication-related ED visits stems from antibiotic side effects.3
- $4.6 billion annually: The estimated cost to treat Americans with infections caused by antimicrobial resistant germs.4
Growing Resistance
- There are 2.8 million resistant infections in the U.S. annually.2
- Over 35,000 Americans die yearly from antimicrobial-resistant infections.2
- By 2050: The toll of drug-resistant infections is predicted to rise by 70%, leading to significant loss of life:5
- 40 million deaths globally each year5
- 2 million deaths in the U.S. each year5
1 Hersh AL, King LM, Shapiro DJ, Hicks LA, Fleming-Dutra KE. Unnecessary Antibiotic Prescribing in US Ambulatory Care Settings, 2010-2015. Clinical Infectious Diseases. 2021;72(1):133-137.
2 Shehab N, Lovegrove MC, Geller AI, et al. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115-2125.
3 Centers for Disease Control and Prevention. (2025). Antimicrobial resistance: Causes and how it spreads.
4 Nelson, R. E., Hatfield, K. M., Wolford, H., et al. (2021). National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clinical Infectious Diseases, 72(Suppl 1), S17-S26.
5 Nature. 40 million deaths by 2050: Toll of drug-resistant infections to rise by 70%.
The HealthTrack Solution:
Next-Morning PCR Results
HealthTrack delivers next-morning results nationwide, giving providers the clarity needed to reduce avoidable return visits, repeat testing, and unnecessary prescribing.
Real-world savings
- PCR for respiratory infection yielded $1,859 lower spending and 3.6 fewer outpatient visits vs. patients not tested.6
- Multiplex vaginal panels saved ~$1,000+ per patient through reduced return visits.7
- PCR-guided therapy cut pharmacy cost to $35.90 PMPM vs. $61.10 with culture.8
The HealthTrack Solution:
Next-Morning PCR Results
HealthTrack delivers next-morning results nationwide, giving providers the clarity needed to reduce avoidable return visits, repeat testing, and unnecessary prescribing.
Real-world savings
- PCR for respiratory infection yielded $1,859 lower spending and 3.6 fewer outpatient visits vs. patients not tested.6
- Multiplex vaginal panels saved ~$1,000+ per patient through reduced return visits.7
- PCR-guided therapy cut pharmacy cost to $35.90 PMPM vs. $61.10 with culture.8
6 Evans, A., Reddy, J., Singh, V., Fragala, M. S., Upadhyay, P., & French, A. (2024). Molecular testing for respiratory tract infections may reduce short-term healthcare costs: A retrospective analysis. American Journal of Infectious Diseases, 20(3), 46-49. https://doi.org/10.3844/ajidsp.2024.46.49.
7 Evans, A., Goldberg, S., Fragala, M., & Reddy, J. (2025, January 16). Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis. HealthTrack.
8Evans A, Doshi R, Yeaw J, Coyle K, Goldberg SE, Wang EJ, Fragala MS, Reddy J. Health care utilization and cost of diagnostic testing for respiratory infections. Am J Manag Care. 2025 Sep 1;31(9):e249-e257. doi: 10.37765 ajmc.2025.89789. PMID: 40966599.
Accuracy Matters
HealthTrack delivers reliable answers and more cost-efficient care.
- High Specificity: Accurately identifies target pathogens minimizing the risk of false positives
- High Sensitivity: Identifies pathogens when other methods may yield false negative
- Quality Control: High standards minimize contamination risk and ensure consistency
- Versatility: Detects a broad range of pathogens from a single sample
Accuracy Matters
HealthTrack delivers reliable answers and more cost-efficient care.
- High Specificity: Accurately identifies target pathogens minimizing the risk of false positives
- High Sensitivity: Identifies pathogens when other methods may yield false negative
- Quality Control: High standards minimize contamination risk and ensure consistency
- Versatility: Detects a broad range of pathogens from a single sample
Expanded Testing, Lower Costs
HealthTrack removes the tradeoff between diagnostic completeness and cost, enabling broader pathogen detection in a single test when clinically appropriate—reducing repeat testing, revisits, and total cost of care.
How HealthTrack Moves Care Forward
How HealthTrack Moves Care Forward
Lower Total Cost of Care
Faster Diagnosis, Reduced Utilization
Sustainable, Evidence-Based Care
1 Evans, A et al. Healthcare Resource Utilization and Costs Among Patients Receiving Diagnostic Tests for Respiratory Infection s. American Journal of Managed Care (Under Review).
2 Evans, A et al. Healthcare Utilization and Costs Following Molecular Diagnostic Testing Among Patients with Vaginitis. Journal of Comparative Effectiveness Research (Accepted).
3 Evans, A et al. Utilization of Syndromic Vaginitis Diagnostic Testing Reduces 6-Month Follow-Up Outpatient Service Healthcare Costs—A Real-World Data Analysis. MDPI Healthcare. 2024.
Improving Patient Outcomes by the Numbers
HealthTrack PCR testing outperforms other approaches and saves money nationwide—Zip Code to Zip Code
Elevating the Patient Experience
Evolving Antibiotic Prescribing
Data is based on 04/2025 HealthTrack VoC Survey. Respondents include over 700 MDs, PAs and NPs within urgent care, primary care, women’s health and pediatric practices.
1 Evans, A et al. Healthcare Resource Utilization and Costs Among Patients Receiving Diagnostic Tests for Respiratory Infection s. American Journal of Managed Care (Under Review).
2 Evans, A et al. Healthcare Utilization and Costs Following Molecular Diagnostic Testing Among Patients with Vaginitis. Journal of Comparative Effectiveness Research (Accepted).
3 Evans, A et al. Utilization of Syndromic Vaginitis Diagnostic Testing Reduces 6-Month Follow-Up Outpatient Service Healthcare Costs—A Real-World Data Analysis. MDPI Healthcare. 2024.
Improving Patient Outcomes by the Numbers
HealthTrack PCR testing outperforms other approaches and saves money nationwide—Zip Code to Zip Code
Elevating the Patient Experience
Evolving Antibiotic Prescribing
Data is based on 04/2025 HealthTrack VoC Survey. Respondents include over 700 MDs, PAs and NPs within urgent care, primary care, women’s health and pediatric practices.
HealthTrack Next-Morning PCR Testing
Equal Access for Everyone
HealthTrack Next-Morning PCR Testing
Equal Access for Everyone
Questions Asked & Answered
Driving Advocacy with Policymakers: The Ask
HealthTrack is calling for sensible coverage policies ensuring patients receive timely molecular testing no matter where they live — improving outcomes and lowering total cost.
The technology is proven. The infrastructure is in place. What’s needed now is policy alignment.
Driving Advocacy with Policymakers: The Ask
HealthTrack is calling for sensible coverage policies ensuring patients receive timely molecular testing no matter where they live — improving outcomes and lowering total cost.
The technology is proven. The infrastructure is in place. What’s needed now is policy alignment.
We can evolve healthcare delivery, together.
Talk to HealthTrack about reducing downstream cost and strengthening the future of modern diagnostic care.
We can evolve healthcare delivery, together.
Talk to HealthTrack about reducing downstream cost and strengthening the future of modern diagnostic care.